Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses its proprietary Drug Response Predictor (DRP) platform, a gene-expression-based technology designed to identify patients who are more likely to respond to specific anticancer treatments.

Allarity’s development strategy combines novel or repurposed oncology therapies with companion diagnostic tools intended to support patient selection. Its programs have included stenoparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and dovitinib, a multikinase inhibitor evaluated in connection with the company’s DRP technology. The company’s pipeline and development priorities have changed over time as clinical and regulatory evaluations have progressed.

The company has roots in Denmark, where it operated as Oncology Venture A/S before adopting the Allarity Therapeutics name, and it has pursued research, clinical development and corporate activities across the United States and Europe. Allarity’s shares trade on the Nasdaq Capital Market under the symbol ALLR.

Key Stats

• Today's Range: $0.99 to $1.04
• 50-Day Range: $0.97 to $1.43
• 52-Week Range: $0.77 to $1.84
• Volume: 97,037 shs
• Average Volume: 118,282 shs
• Market Capitalization: $15.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.25
• Consensus Rating: Hold

Allarity Therapeutics Stock Analysis - MarketRank™

Allarity Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 724th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Allarity Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Allarity Therapeutics has a consensus price target of $10.25, representing about 935.4% upside from its current price of $0.99.

Amount of Analyst Coverage

Allarity Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allarity Therapeutics are expected to decrease in the coming year, from ($0.80) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allarity Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allarity Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allarity Therapeutics has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of Allarity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allarity Therapeutics has a short interest ratio ("days to cover") of 0.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allarity Therapeutics has recently increased by 6.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allarity Therapeutics does not currently pay a dividend.

Dividend Growth

Allarity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.16% of the stock of Allarity Therapeutics is held by insiders.

Percentage Held by Institutions

11.53% of the stock of Allarity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 8
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Allarity Therapeutics: $10.25
• High Price Target: $10.25
• Low Price Target: $10.25
• Potential Upside/Downside: +935.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -152.77%
• Return on Assets: -46.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.11
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $345 thousand
• Price / Sales: 45.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 1.62

Miscellaneous

• Outstanding Shares: 15,911,000
• Free Float: 15,886,000
• Market Cap: $15.75 million
• Optionable: Not Optionable
• Beta: 0.57